NSE:CAPLIPOINTNSEHealthcare
Caplin Point Laboratories Limited
📊 Drug Manufacturers - Specialty & Generic
Day ₹1,720
₹1,741 Overbought
52W ₹1,500
₹2,395 Oversold
₹1,735.60
▲ ₹3.40 (+0.20%)
Vol: 19,300 · Avg: 78,793
As of April 29, 2026 · 06:27 IST
COMPOSITE RISK SCORE
70 LOW RISK
VAL:20/25 · FIN:18/25 · GRO:16/25 · TECH:16/25
📈 P/E RATIO
21.5x
Trailing
📖 P/B RATIO
4.3x
Price to Book
💰 EPS
₹80.55
TTM
🏛 MARKET CAP
₹13,193Cr
Mid Cap
📊 ROE
18.8%
Return on Equity
📈 REV GROWTH
10.1%
YoY
🏢 Company Analysis · Caplin Point Laboratories Limited
💼 BUSINESS MODEL
  • Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India..
  • The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion..
  • It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags..
  • Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India..
  • Operates in Drug Manufacturers - Specialty & Generic within the Healthcare sector.
  • Workforce of 3,966 employees.
🏰 MOAT & COMPETITION
  • Mid-cap (₹13,193 Cr) — growing company in a competitive landscape.
  • Profit margin of 29.3% suggests pricing power / cost moat.
  • Key competitors: Glaxosmi. Pharma, Sun Pharma.Inds., Abbott India, Biocon.
🚀 CATALYSTS
  • Company has delivered good profit growth of 20.5% CAGR over last 5 years
  • Company's median sales growth is 21.6% of last 10 years
⚖️ ASYMMETRY CHECK
  • Analyst target range: ₹2,500 — ₹2,500 (mean ₹2,500, 1 analysts).
  • Unfavorable asymmetry — limited upside +44% vs downside +44% (1.0x).
  • P/E of 21.5x — fair value territory; catalysts needed for re-rating.
🔭 FUTURE OUTLOOK
  • Analyst consensus: None (1 analysts).
  • Latest quarter earnings grew 18% YoY — positive trajectory.
✅ PROS
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 20.5% CAGR over last 5 years
  • Company's median sales growth is 21.6% of last 10 years
❌ CONS
  • None identified
VALUATION
20/25
25% WEIGHT
  • P/E at 22x
  • P/B at 4.3x
  • Analyst target: ₹2500 (+44.0%)
  • 1Y return: -6.9%
FINANCIAL HEALTH
18/25
25% WEIGHT
  • ROE: 18.8%
  • Profit margin: 29.3%
  • Revenue growth: 10.1%
  • Debt/Equity: 0%
GROWTH
16/25
25% WEIGHT
  • Revenue growth: 10.1%
  • Earnings growth: 18.3%
  • Beta: 0.11
  • Sector: Healthcare
TECHNICAL
16/25
25% WEIGHT
  • RSI, MACD, MA crossovers
  • 200 DMA & 50 EMA position
  • Volume trend analysis
  • Price momentum signals
📈 Price Movement
🕯 Candlestick Chart
🎯 Price Prediction · Analyst Target Cone Source: Yahoo Finance Analyst Targets ↗
📉 Valuation Trends (at current CMP)
P/E Ratio at current CMP
583.6 442.3 300.9 159.6 18.3 2014 2015 '2016 9m '2017 '2018 '2019 '2020 '2021 '2022 '2023 '2024 '2025 TTM Jun 2014: 507.5 Jun 2015: 319.6 Mar 2016 9m: 286.9 Mar 2017: 137.2 Mar 2018: 90.6 Mar 2019: 74.3 Mar 2020: 61.1 Mar 2021: 54.2 Mar 2022: 43.9 Mar 2023: 35.0 Mar 2024: 28.8 Mar 2025: 24.6 TTM: 21.5 21.5
💎 Valuation & Financial Metrics
P/E RATIO
21.5x
Trailing twelve months
P/B RATIO
4.3x
Price to Book value
ROE
18.8%
Return on Equity
PROFIT MARGIN
29.3%
Net profit margin
OPM
31.4%
Operating profit margin
ANALYST TARGET
₹2,500
Range: ₹2,500 - ₹2,500
Yahoo Finance ↗
PEG RATIO
1.02
Price/Earnings to Growth
EV/EBITDA
16.8x
Enterprise value ratio
CURRENT RATIO
N/A
Liquidity measure
DIVIDEND YIELD
0.35%
Annual yield
ROA
17.8%
Return on Assets
GROSS MARGIN
59.2%
Gross profit margin
INDUSTRY AVERAGES — PHARMACEUTICALS
P/E 34.7x (below avg)
P/B 5.0x (sector fair)
ROCE 23.5% (above avg)
ROE 20% (sector good)
OPM 22% (sector good)
Div Yield 0.96%
D/E <20 (sector comfort)
📋 Quarterly Performance Trend
QuarterRevenueQoQ %Net ProfitQoQ %Op. Cash FlowEBITDA Margin
Q2 FY25 ₹483 Cr— ₹131 Cr— N/A 38.4%
Q3 FY25 ₹493 Cr+2.0% ₹139 Cr+6.2% N/A 39.3%
Q4 FY25 ₹486 Cr-1.4% ₹143 Cr+2.6% N/A 39.9%
Q1 FY26 ₹510 Cr+4.9% ₹153 Cr+7.2% N/A 39.4%
Q3 FY26 ₹543 Cr+6.4% ₹164 Cr+7.3% N/A 41.2%
📊 Year-on-Year Trend
FYRevenueYoY %Net ProfitYoY %Op. Cash FlowYoY %
FY22 ₹1,269 Cr— ₹300 Cr— ₹337 Cr—
FY23 ₹1,454 Cr+14.5% ₹376 Cr+25.5% ₹271 Cr-19.4%
FY24 ₹1,680 Cr+15.5% ₹457 Cr+21.5% ₹318 Cr+17.3%
FY25 ₹1,921 Cr+14.4% ₹536 Cr+17.3% ₹432 Cr+35.8%
📈 Revenue vs Earnings
🎯 EPS: Estimate vs Actual
💰 How Caplin Point Laboratories Limited Makes Its Money
Revenue ₹543 Cr Cost of Revenue ₹215 Cr Gross Profit ₹328 Cr Op. Expenses ₹157 Cr Operating Inc. ₹170 Cr Tax ₹38 Cr Other ₹34 Cr Net Income ₹164 Cr (30.2% margin) Dec 2025 · All values in ₹ Crores
🏦 Snapshot of Caplin Point Laboratories Limited's Balance Sheet
Total Assets ₹3.2K Cr Cash & Equiv.: ₹583 Cr (18.2%) Receivables: ₹632 Cr (19.7%) Inventory: ₹336 Cr (10.5%) Other Current: ₹582 Cr (18.1%) PP&E: ₹674 Cr (21.0%) Goodwill: ₹3 Cr (0.1%) Other Non-Curr.: ₹385 Cr (12.0%) Liab. + Equity ₹3.2K Cr Current Liab.: ₹306 Cr (9.5%) Long-Term Debt: ₹3 Cr (0.1%) Equity: ₹2.9K Cr (90.0%) As of Mar 2025 · All values in ₹ Crores
💸 Looking into Caplin Point Laboratories Limited's Cash Flow
Operating CF ₹432 Cr Capital Exp. ₹192 Cr Free Cash Flow ₹241 Cr Dividends ₹38 Cr Retained / Other ₹203 Cr FY2025 · All values in ₹ Crores
📅 Quarterly Results Source: Screener ↗
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +395410436453459483493502510534543
Expenses +269273293308307318331334332345353
Operating Profit127137142145152165162168178189190
OPM %32%34%33%32%33%34%33%33%35%35%35%
Other Income +1221171719213126233034
Interest00000000000
Depreciation1112141616171617161819
Profit before tax127146145146154168177177184201204
Tax %18%20%18%17%19%22%21%18%18%20%19%
Net Profit +104116120121125131140145151160166
EPS in Rs13.6215.1315.4316.0116.3117.2118.2818.7620.1020.3221.56
Raw PDF
📊 Profit & Loss Statement Source: Screener ↗
Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +5406498631,0611,2691,4671,6941,9372,089
Expenses +3454176037328741,0251,1421,2871,365
Operating Profit195232260329395442552651725
OPM %36%36%30%31%31%30%33%34%35%
Other Income +1319412338556692113
Interest110211111
Depreciation192332374745536671
Profit before tax188227269314386451564677766
Tax %23%22%20%20%20%16%18%20%
Net Profit +145177215251308377461541622
EPS in Rs19.1523.3528.4232.0339.5649.5760.1970.5680.74
Dividend Payout %10%9%9%9%10%9%8%8%
🏦 Balance Sheet Source: Screener ↗
Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital151515151515151515
Reserves3495828589541,2521,6492,0842,6193,144
Borrowings +1361132352192222192225
Other Liabilities +136109139159250305380352339
Total Liabilities5007431,1261,3641,7362,1912,6983,2083,504
Fixed Assets +169227272305287280453546555
CWIP1510201418221117144177
Investments4770611189281376590636
Other Assets +2694367721,0331,3431,4101,7531,9282,135
Total Assets5007431,1261,3641,7362,1912,6983,2083,504
💰 Cash Flow Statement Source: Screener ↗
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +68668345269337271318432
Cash from Investing Activity +-36-69-100-54-30-377-216-319-333
Cash from Financing Activity +-7-129080-24-41-28-38-38
Net Cash Flow25-147370215-8127-3961
Free Cash Flow431818-3219524678173241
CFO/OP73%53%54%38%102%106%81%77%86%
📈 Key Financial Ratios
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days30859097969198117119
Inventory Days444447210139149159183159
Days Payable15514476576810284116103
Cash Conversion Cycle-81-1661251166138173184175
Working Capital Days-2947104167145165144166174
ROCE %68%63%45%33%28%28%26%26%26%
🏭 Industry Peers — Pharmaceuticals
#CompanyCMPP/EMkt CapROCEQtr ProfitScore
1Glaxosmi. Pharma ★₹2,38840.2₹40,45463.2%+22.8%58
2Sun Pharma.Inds.₹1,75534.7₹421,13120.2%+18.7%57
3Abbott India₹25,63235.8₹54,46946.2%+4.2%51
4Biocon₹36572.0₹59,1556.2%+1470.0%45
5Zydus Lifesci.₹91818.0₹92,33724.3%+7.7%45
6Lupin₹2,33021.4₹106,52321.3%+76.0%45
7Dr Reddy's Labs₹1,35220.2₹112,81622.7%-14.4%45
8Ajanta Pharma₹2,81534.6₹35,16732.4%+17.6%44
★ Glaxosmi. Pharma ranks higher on combined P/E, ROCE, and growth metrics in Pharmaceuticals
🏛 Shareholding Pattern
Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters70.56%70.56%70.56%70.57%70.57%70.57%
FIIs4.86%5.73%6.16%6.51%6.58%6.15%
DIIs2.11%2.00%2.22%2.10%2.05%2.14%
Public22.48%21.72%21.06%20.82%20.81%21.14%
No. of Shareholders92,70296,38794,16993,75393,70593,896
🟢 CATALYSTS
🏆Positive Revenue Growth: Revenue growing at 10.1% YoY.
💹Healthy Margins (29.3%): Above sector norm of 22%.
🔀Analyst Upside (44%): Mean target of ₹2500 above current price.
🇮Low Beta (0.11): Less volatile than market — defensive play.
🇳Earnings Growth (18%): Above sector norm — strong profit expansion.
🔴 RISKS
📜Market Risk: Broader market correction or sentiment shift could impact stock.
💰Sector Risk: Regulatory or competitive changes in Healthcare space.
🔓Execution Risk: Growth may not meet elevated expectations.
🕸 Factor Analysis · Radar
Momentum 6/10: 1M +15.3%, 6M -14.1%, RSI 56, MACD bullish, Below 200DMA Sentiment 8/10: Analyst upside +44.0%, Rec: none Value 6/10: P/E 21.5, P/B 4.3, PEG 1.02, EV/EBITDA 16.8 Quality 7/10: Margin 29.3%, D/E 0 Low Volatility 9/10: Beta 0.11, Ann. vol 31% Momentum 6 Sentiment 8 Value 6 Quality 7 Low Vol 9
Momentum 6/10
1M +15.3%, 6M -14.1%, RSI 56, MACD bullish, Below 200DMA
Sentiment 8/10
Analyst upside +44.0%, Rec: none
Value 6/10
P/E 21.5, P/B 4.3, PEG 1.02, EV/EBITDA 16.8
Quality 7/10
Margin 29.3%, D/E 0
Low Volatility 9/10
Beta 0.11, Ann. vol 31%
🎯 Decision Matrix
ActionIf Stock RisesIf Stock Falls
BUYCapture 44.0% analyst upside; strong 26% ROCE compoundsOPM of 31% provides margin buffer
HOLDRetain existing position; wait for better entry; FII stake falling (-0.43%)Miss further upside if momentum continues; 1M return of +15.3% shows momentum
SELLLock in -6.9% 1Y returnAvoid further drawdown
REASONS TO BUY
  • Analyst upside of 44.0% with mean target of ₹2,500
  • ROCE at 26% indicates strong capital efficiency
  • Revenue growing at 10.1% YoY (sector norm: 10%)
  • Operating margin of 31% shows pricing power (sector norm: 22%)
REASONS TO SELL / AVOID
  • FII stake falling (-0.43%) — institutional exit signal
📰 Latest News
Caplin Point Laboratories Ltd (BOM:524742) Q3 2026 Earnings Call Highlights: Navigating Growth ...
GuruFocus.com · 2026-02-05T17:03
Caplin Point Laboratories Ltd (BOM:524742) Q2 2026 Earnings Call Highlights: Strong Revenue ...
GuruFocus.com · 2025-11-06T19:01
RECOMMENDATION
BUY
COMPOSITE SCORE
70/100
Caplin Point Laboratories Limited trades at ₹1,735.60 with a composite risk score of 70/100. The stock scores 20/25 on valuation, 18/25 on financial health, 16/25 on growth, and 16/25 on technicals. The company is currently profitable with strong return on equity.

Analyst consensus suggests upside of 44.0% with a mean target of ₹2500. Revenue growth is at 10.1%.

Within Pharmaceuticals, Glaxosmi. Pharma (P/E 40.2, ROCE 63.2%) ranks higher on techno-fundamental metrics and may be worth considering.

Bottom Line: Attractive risk/reward for Healthcare at current levels. The current recommendation is BUY.
PROFITABLE HIGH ROE UPSIDE POTENTIAL
RISK SCORE REPORT · NSE:CAPLIPOINT · GENERATED APR 29, 2026 06:27 IST · DATA VIA YAHOO FINANCE + SCREENER.IN
DISCLAIMER: THIS IS NOT FINANCIAL ADVICE. DATA MAY BE DELAYED. ALWAYS VERIFY WITH OFFICIAL SOURCES BEFORE INVESTING.